3 reports of this reaction
4.3% of all CALCAREA PHOSPHORICA reports
#15 most reported adverse reaction
PULMONARY EMBOLISM is the #15 most commonly reported adverse reaction for CALCAREA PHOSPHORICA, manufactured by ANI Pharmaceuticals, Inc.. There are 3 FDA adverse event reports linking CALCAREA PHOSPHORICA to PULMONARY EMBOLISM. This represents approximately 4.3% of all 70 adverse event reports for this drug.
Patients taking CALCAREA PHOSPHORICA who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is moderately reported among CALCAREA PHOSPHORICA users, representing a notable but not dominant share of adverse events.
In addition to pulmonary embolism, the following adverse reactions have been reported for CALCAREA PHOSPHORICA:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 3 FDA reports for CALCAREA PHOSPHORICA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 4.3% of all adverse event reports for CALCAREA PHOSPHORICA, making it a notable side effect.
If you experience pulmonary embolism while taking CALCAREA PHOSPHORICA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.